Your browser doesn't support javascript.
loading
Utility and Safety of Backup Insulin Regimens Generated by the Bionic Pancreas: A Randomized Study.
Mauras, Nelly; Damiano, Edward R; El-Khatib, Firas H; Marak, Martin Chase; Calhoun, Peter; Ruedy, Katrina J; Balliro, Courtney; Li, Zoey; Beck, Roy W; Russell, Steven J.
Afiliação
  • Mauras N; Division of Pediatric Endocrinology, Diabetes & Metabolism, Nemours Children's Health, Jacksonville, Florida, USA.
  • Damiano ER; Beta Bionics, Concord, Massachusetts, USA.
  • El-Khatib FH; Beta Bionics, Concord, Massachusetts, USA.
  • Marak MC; Jaeb Center for Health Research, Tampa, Florida, USA.
  • Calhoun P; Jaeb Center for Health Research, Tampa, Florida, USA.
  • Ruedy KJ; Jaeb Center for Health Research, Tampa, Florida, USA.
  • Balliro C; Beta Bionics, Concord, Massachusetts, USA.
  • Li Z; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Beck RW; Jaeb Center for Health Research, Tampa, Florida, USA.
  • Russell SJ; Jaeb Center for Health Research, Tampa, Florida, USA.
Diabetes Technol Ther ; 25(6): 437-441, 2023 06.
Article em En | MEDLINE | ID: mdl-36877259
ABSTRACT
The bionic pancreas (BP) is initialized with body weight only and doses insulin autonomously without carbohydrate counting, instead using qualitative meal announcements. In case of device malfunction, the BP generates and continuously updates backup insulin doses for injection or pump users, including long-acting insulin dose, a four-period basal insulin profile, short-acting meal doses, and a glucose correction factor. Following a 13-week trial in type 1 diabetes, participants using the BP (6-83 years) completed 2-4 days, in which they were randomly assigned to their prestudy insulin regimen (N = 147) or to follow BP-provided guidance (N = 148). Glycemic outcomes with BP guidance were similar to those reinstituting their prestudy insulin regimen, with both groups having higher mean glucose and lower time-in-range than while using the BP during the 13-week trial. In conclusion, a backup insulin regimen automatically generated by the BP can be safely implemented if need arises to discontinue use of the BP. Clinical Trial Registry clinicaltrials.gov; NCT04200313.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pâncreas Artificial / Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Guideline / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pâncreas Artificial / Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Guideline / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article